Rezatapopt

N/A

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameRezatapopt
Drug Alias NamePC-14586PC-586
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP53 gene stimulants
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeItaly +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPMV Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterPMV Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[15] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A